TB-500 is routinely described as the healing peptide for tendons and muscle. It is a fragment of a naturally occurring protein with a real preclinical literature — and a human evidence base that stops well short of the claims.
TB-500 occupies a strange position: it is discussed as though it were a known therapy, while the molecule most of the research concerns is not the molecule being sold. Untangling that is the first useful step.
Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found in most human cells and in wound fluid. It is an actin-sequestering protein — its best-characterised biological role concerns actin dynamics, cell migration and cytoskeletal organisation.
TB-500 is a short synthetic fragment associated with the active region of Tβ4, sold as a research chemical. It is not the same molecule as the full-length protein studied in most published research, and the two are not interchangeable in a scientific claim. When a marketing page cites Tβ4 literature to describe TB-500, that substitution is doing unacknowledged work.
The foundational work is genuine. A 1999 study in the Journal of Investigative Dermatology reported that thymosin β4 accelerated wound healing in rodent models, with increased cell migration and collagen deposition in dermal wounds. Subsequent laboratory work explored effects on corneal repair, cardiac tissue after ischaemic injury, and cell migration in a range of models. A 2015 review by Goldstein and Kleinman — the authors most associated with the field — summarised the mechanistic picture and the early clinical development programme.
What that literature supports is a plausible biological mechanism in tissue repair. What it does not supply is a demonstrated clinical effect on human tendon, muscle or ligament injury from the fragment sold online.
A credible mechanism and a proven treatment are different claims that require different evidence.
Thymosin β4 has been examined in early-phase human studies in specific indications, principally ophthalmic and dermal wound settings. That is a considerably narrower record than the musculoskeletal claims made for TB-500, and it does not include completed, published phase 3 trials establishing efficacy in tendon or muscle injury. For TB-500 specifically, there is no published randomised controlled human trial establishing efficacy or a safety profile, and no established human dosing range. Any figure circulating for it is therefore unsupported, and this publication does not supply one.
WADA. Thymosin β4 and TB-500 fall under the Prohibited List as non-approved substances (category S0), prohibited at all times. For any athlete under anti-doping rules, use is a sanctionable risk irrespective of effect.
Medicines regulators. TB-500 is not an approved medicine in the United States or the European Union. Material sold under that name sits outside the pharmaceutical supply chain, where identity, purity, sterility and endotoxin content are not verified by any regulator — a category of risk the FDA has repeatedly warned about for unapproved peptide products.
Check which molecule a cited study used: full-length Tβ4 or a fragment. Most cited studies used the former.
Check the species. Rodent and in-vitro results are the bulk of the literature.
Check the indication. Corneal or dermal wound research does not describe an Achilles tendon.
Thymosin beta-4 is a real protein with a real and interesting repair-biology literature. TB-500 is a synthetic fragment that borrows that literature's authority without having earned it in human trials. The accurate position is that the mechanism is worth studying, the human evidence for the marketed compound does not exist, and the compound remains prohibited in sport and unapproved as a medicine.
The listed sources are the primary material: the 1999 wound-healing study and the 2015 review for the scientific record, and the WADA and FDA positions for regulatory status.